Next-generation sequencing (NGS) and microarray technologies are essential resources for investigating the genomic and molecular underpinnings of cancer formation, progression, and clinical outcomes. The primary objective of the Cancer Genomics Shared Resource (CGSR) is to maximize the scientific and clinical impact of research by Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) members. This is accomplished by providing rapid and cost-effective access to state-of-the-art genomic technologies, while creating a unifying environment that cultivates scientific awareness, education, and collaboration. The CGSR supports the WFBCCC's mission by providing cancer-prioritized access to comprehensive microarray and NGS technologies and offers seamless data flow through to the Biostatistics and Bioinformatics Shared Resource - for bioinformatics support. In October 2014, at the instigation of Director Pasche, the former Microarray Core Laboratory (2002-2014; which received a score of ?excellent? in the prior critique) was renamed the Cancer Genomics Shared Resource to reflect the integration of the WFBCCC's microarray core competencies with the NGS expertise of the Center for Genomics and Personalized Medicine Research. This new joint-Center partnership reflects the strategic plans of the WFBCCC and the Wake Forest School of Medicine (WFSOM), as well as supporting priority recommendations of the WFSOM Centers and Cores Advisory Committee. The CGSR provides cutting-edge genomic services, prioritizes cancer-specific research, creates an optimal environment for the Institution's rapidly developing precision medicine initiative, and seamlessly integrates with other key Shared Resources within the WFBCCC to promote integrated, high-quality workflows for cancer genomics research. The CGSR is led by Co-Directors Lance Miller, Ph.D., and Greg Hawkins, Ph.D., who have established records in cancer genomics research, and is operated by four experienced technicians (two at 100% effort, one at 50% effort and one at 5% effort). A bioinformatician devotes 30% of effort to CGSR daily operations. In the most recent grant year (11/01/14-10/31/15), the CGSR operated at 80-90% FTE utilization to provide 1,144 services to 20 investigators, 75% of which were WFBCCC investigators. Compared to previous years, the CGSR doubled its service output and increased its cancer-specific service output by approximately 50%. The CGSR directly contributes to the scientific achievements of WFBCCC investigators by generating high-quality and cost-effective data that will translate into new discoveries, publications, grant awards, and grant applications. Further development of CGSR's role in supporting the development and productivity of WFBCCC Disease-Oriented Teams and the continued development of seamless workflows across Shared Resources are expected to enhance translational genomics initiatives at the WFBCCC.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wake Forest University Health Sciences
United States
Zip Code
Paek, M-S; Nightingale, C L; Tooze, J A et al. (2018) Contextual and stress process factors associated with head and neck cancer caregivers' physical and psychological well-being. Eur J Cancer Care (Engl) 27:e12833
Dutta, Samrat; Rivetti, Claudio; Gassman, Natalie R et al. (2018) Analysis of single, cisplatin-induced DNA bends by atomic force microscopy and simulations. J Mol Recognit 31:e2731
Pardee, Timothy S; Anderson, Rebecca G; Pladna, Kristin M et al. (2018) A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res 24:2060-2073
Atkins, Hannah M; Appt, Susan E; Taylor, Robert N et al. (2018) Systemic Iron Deficiency in a Nonhuman Primate Model of Endometriosis. Comp Med 68:298-307
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594
Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208

Showing the most recent 10 out of 548 publications